세계의 신경 재생 치료 시장 : 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2024-2034년)
Neuroregeneration Therapy Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034
상품코드:1552658
리서치사:Transparency Market Research
발행일:2024년 07월
페이지 정보:영문 146 Pages
라이선스 & 가격 (부가세 별도)
한글목차
신경 재생 치료 시장 - 조사 범위
TMR의 조사 보고서 "세계 신경 재생 치료 시장"은 2024년부터 2034년까지의 예측 기간 동안 시장 지표에 대한 귀중한 통찰력을 얻기 위해 과거뿐만 아니라 현재의 성장 동향과 기회도 조사했습니다. 이 보고서는 2024년을 기준연도로, 2034년을 예측연도로 하여 2018년부터 2034년까지 세계 신경재생치료 시장의 수익과 예측을 제공합니다. 또한 2024년부터 2034년까지 세계 신경재생치료 시장의 연평균 성장률(CAGR%)도 제시합니다.
이 보고서는 광범위한 조사를 통해 작성되었으며, 1차 조사에서 애널리스트는 KOL(Key Opinion Leader), 업계 리더 및 오피니언 제조업체를 인터뷰하고, 2차 조사에서는 주요 기업의 제품 자료, 연례 보고서, 보도 자료 및 관련 자료를 참조하여 신경 재생 치료제 시장을 추론했습니다, 신경재생치료 시장을 추론하였습니다.
시장 현황
2023년 시장 규모
370억 달러
2034년 시장 규모
648억 달러
CAGR
5.3%
이 보고서는 세계 신경 재생 치료 시장 경쟁 구도를 심층적으로 분석합니다. 세계 신경재생치료 시장에서 사업을 운영하는 주요 기업들이 확인되었으며, 각 기업들은 다양한 속성으로 프로파일링되어 있습니다. 기업 개요, 재무 상태, 최근 동향, SWOT 등은 이 보고서에서 다루는 세계 신경 재생 치료 시장 기업의 속성입니다.
목차
제1장 서문
제2장 전제조건과 조사 방법
제3장 주요 요약 : 세계 시장
제4장 시장 개요
서론
개요
시장 역학
세계 시장 분석과 예측, 2020-2034년
제5장 주요 인사이트
파이프라인 분석
주요 제품/브랜드 분석
주요 M&A
COVID-19의 산업에 대한 영향
제6장 세계 시장 분석과 예측 : 약제 유형별
서론과 정의
주요 조사 결과와 발전
시장 매출 예측 : 약제 유형별, 2020-2034년
N-methyl-D-asparate Receptor Antagonists
콜린에스테라아제 억제제
도파민 작용제
면역 조절제
기타
시장의 매력 : 약제 유형별
제7장 세계 시장 분석과 예측 : 적응증 유형별
서론과 정의
주요 조사 결과와 발전
시장 매출 예측 : 적응증 유형별, 2020-2034년
파킨슨병
알츠하이머병
다발성 경화증
헌팅턴병
기타
시장 매력도 : 적응증 유형별
제8장 세계 시장 분석과 예측 : 투여 경로별
서론과 정의
주요 조사 결과와 발전
시장 매출 예측 : 투여 경로별, 2020-2034년
경구
비경구
경피
시장의 매력 : 투여 경로별
제9장 세계 시장 분석과 예측 : 최종사용자별
서론과 정의
주요 조사 결과와 발전
시장 매출 예측 : 최종사용자별, 2020-2034년
병원 약국
소매 약국
온라인 약국
시장의 매력 : 최종사용자별
제10장 세계 시장 분석과 예측 : 지역별
주요 조사 결과
시장 매출 예측 : 지역별, 2020-2034년
북미
유럽
아시아태평양
라틴아메리카
중동 및 아프리카
시장의 매력 : 지역별
제11장 북미 시장 분석과 예측
제12장 유럽 시장 분석과 예측
제13장 아시아태평양 시장 분석과 예측
제14장 라틴아메리카 시장 분석과 예측
제15장 중동 및 아프리카 시장 분석과 예측
제16장 경쟁 구도
시장 기업 - 경쟁 매트릭스(기업 Tier 및 규모별)
시장 점유율 분석 : 기업별(2023년)
기업 개요
Biogen
Merck & Co., Inc.
Novartis AG
Teva Pharmaceutical Industries Ltd.
Orion Corporation
UCB
Acadia Pharmaceuticals Inc.
Mitsubishi Chemical Group Corporation
H. Lundbeck A/S
Denali Therapeutics
Aquinnah Pharmaceuticals
Prevail Therapeutics
AZTherapies, Inc.
LSH
영문 목차
영문목차
Neuroregeneration Therapy Market - Scope of Report
TMR's report on the global neuroregeneration therapy market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global neuroregeneration therapy market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global neuroregeneration therapy market from 2024 to 2034.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the neuroregeneration therapy market.
Market Snapshot
Market Value in 2023
US$ 37 Bn
Market Value in 2034
US$ 64.8 Bn
CAGR
5.3%
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global neuroregeneration therapy market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global neuroregeneration therapy market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global neuroregeneration therapy market.
The report delves into the competitive landscape of the global neuroregeneration therapy market. Key players operating in the global neuroregeneration therapy market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global neuroregeneration therapy market profiled in this report.
Key Questions Answered in Global neuroregeneration therapy Market Report:
What is the sales/revenue generated by neuroregeneration therapy across all regions during the forecast period?
What are the opportunities in the global neuroregeneration therapy market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2034?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?
Neuroregeneration Therapy Market - Research Objectives and Research Approach
The comprehensive report on the global neuroregeneration therapy market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global neuroregeneration therapy market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global neuroregeneration therapy market.
Table of Contents
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Neuroregeneration Therapy Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Neuroregeneration Therapy Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Neuroregeneration Therapy Market Analysis and Forecast, by Drug Type
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Type, 2020-2034
6.3.1. N-methyl-D-asparate Receptor Antagonists
6.3.2. Cholinesterase Inhibitors
6.3.3. Dopamine Agonists
6.3.4. Immunomodulatory Drugs
6.3.5. Others
6.4. Market Attractiveness, by Drug Type
7. Global Neuroregeneration Therapy Market Analysis and Forecast, by Indication Type
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Indication Type, 2020-2034
7.3.1. Parkinson's Disease
7.3.2. Alzheimer's Disease
7.3.3. Multiple Sclerosis
7.3.4. Huntington Disease
7.3.5. Others
7.4. Market Attractiveness, by Indication Type
8. Global Neuroregeneration Therapy Market Analysis and Forecast, by Route of Administration
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Route of Administration, 2020-2034
8.3.1. Oral
8.3.2. Parenteral
8.3.3. Transdermal
8.4. Market Attractiveness, by Route of Administration
9. Global Neuroregeneration Therapy Market Analysis and Forecast, by End-user
9.1. Introduction and Definitions
9.2. Key Findings/Developments
9.3. Market Value Forecast, by End-user, 2020-2034
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. Market Attractiveness, by End-user
10. Global Neuroregeneration Therapy Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2020-2034
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness, by Region
11. North America Neuroregeneration Therapy Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Type, 2020-2034
11.2.1. N-methyl-D-asparate Receptor Antagonists
11.2.2. Cholinesterase Inhibitors
11.2.3. Dopamine Agonists
11.2.4. Immunomodulatory Drugs
11.2.5. Others
11.3. Market Attractiveness, by Drug Type
11.4. Market Value Forecast, by Indication Type, 2020-2034
11.4.1. Parkinson's Disease
11.4.2. Alzheimer's Disease
11.4.3. Multiple Sclerosis
11.4.4. Huntington Disease
11.4.5. Others
11.5. Market Attractiveness, by Indication Type
11.6. Market Value Forecast, by Route of Administration, 2020-2034
11.6.1. Oral
11.6.2. Parenteral
11.6.3. Transdermal
11.7. Market Attractiveness, by Route of Administration
11.8. Market Value Forecast, by End-user, 2020-2034
11.8.1. Hospital Pharmacies
11.8.2. Retail Pharmacies
11.8.3. Online Pharmacies
11.9. Market Attractiveness, by End-user
11.10. Market Value Forecast, by Country/Sub-region, 2020-2034
11.10.1. U.S.
11.10.2. Canada
11.11. Market Attractiveness Analysis
11.11.1. By Drug Type
11.11.2. By Indication Type
11.11.3. By Route of Administration
11.11.4. By End-user
11.11.5. By Country
12. Europe Neuroregeneration Therapy Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Type, 2020-2034
12.2.1. N-methyl-D-asparate Receptor Antagonists
12.2.2. Cholinesterase Inhibitors
12.2.3. Dopamine Agonists
12.2.4. Immunomodulatory Drugs
12.2.5. Others
12.3. Market Attractiveness, by Drug Type
12.4. Market Value Forecast, by Indication Type, 2020-2034
12.4.1. Parkinson's Disease
12.4.2. Alzheimer's Disease
12.4.3. Multiple Sclerosis
12.4.4. Huntington Disease
12.4.5. Others
12.5. Market Attractiveness, by Indication Type
12.6. Market Value Forecast, by Route of Administration, 2020-2034
12.6.1. Oral
12.6.2. Parenteral
12.6.3. Transdermal
12.7. Market Attractiveness, by Route of Administration
12.8. Market Value Forecast, by End-user, 2020-2034
12.8.1. Hospital Pharmacies
12.8.2. Retail Pharmacies
12.8.3. Online Pharmacies
12.9. Market Attractiveness, by End-user
12.10. Market Value Forecast, by Country/Sub-region, 2020-2034
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Rest of Europe
12.11. Market Attractiveness Analysis
12.11.1. By Drug Type
12.11.2. By Indication Type
12.11.3. By Route of Administration
12.11.4. By End-user
12.11.5. By Country/Sub-region
13. Asia Pacific Neuroregeneration Therapy Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Type, 2020-2034
13.2.1. N-methyl-D-asparate Receptor Antagonists
13.2.2. Cholinesterase Inhibitors
13.2.3. Dopamine Agonists
13.2.4. Immunomodulatory Drugs
13.2.5. Others
13.3. Market Attractiveness, by Drug Type
13.4. Market Value Forecast, by Indication Type, 2020-2034
13.4.1. Parkinson's Disease
13.4.2. Alzheimer's Disease
13.4.3. Multiple Sclerosis
13.4.4. Huntington Disease
13.4.5. Others
13.5. Market Attractiveness, by Indication Type
13.6. Market Value Forecast, by Route of Administration, 2020-2034
13.6.1. Oral
13.6.2. Parenteral
13.6.3. Transdermal
13.7. Market Attractiveness, by Route of Administration
13.8. Market Value Forecast, by End-user, 2020-2034
13.8.1. Hospital Pharmacies
13.8.2. Retail Pharmacies
13.8.3. Online Pharmacies
13.9. Market Attractiveness, by End-user
13.10. Market Value Forecast, by Country/Sub-region, 2020-2034
13.10.1. China
13.10.2. Japan
13.10.3. India
13.10.4. Australia & New Zealand
13.10.5. Rest of Asia Pacific
13.11. Market Attractiveness Analysis
13.11.1. By Drug Type
13.11.2. By Indication Type
13.11.3. By Route of Administration
13.11.4. By End-user
13.11.5. By Country/Sub-region
14. Latin America Neuroregeneration Therapy Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Drug Type, 2020-2034
14.2.1. N-methyl-D-asparate Receptor Antagonists
14.2.2. Cholinesterase Inhibitors
14.2.3. Dopamine Agonists
14.2.4. Immunomodulatory Drugs
14.2.5. Others
14.3. Market Attractiveness, by Drug Type
14.4. Market Value Forecast, by Indication Type, 2020-2034
14.4.1. Parkinson's Disease
14.4.2. Alzheimer's Disease
14.4.3. Multiple Sclerosis
14.4.4. Huntington Disease
14.4.5. Others
14.5. Market Attractiveness, by Indication Type
14.6. Market Value Forecast, by Route of Administration, 2020-2034
14.6.1. Oral
14.6.2. Parenteral
14.6.3. Transdermal
14.7. Market Attractiveness, by Route of Administration
14.8. Market Value Forecast, by End-user, 2020-2034
14.8.1. Hospital Pharmacies
14.8.2. Retail Pharmacies
14.8.3. Online Pharmacies
14.9. Market Attractiveness, by End-user
14.10. Market Value Forecast, by Country/Sub-region, 2020-2034
14.10.1. Brazil
14.10.2. Mexico
14.10.3. Rest of Latin America
14.11. Market Attractiveness Analysis
14.11.1. By Drug Type
14.11.2. By Indication Type
14.11.3. By Route of Administration
14.11.4. By End-user
14.11.5. By Country/Sub-region
15. Middle East & Africa Neuroregeneration Therapy Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Drug Type, 2020-2034
15.2.1. N-methyl-D-asparate Receptor Antagonists
15.2.2. Cholinesterase Inhibitors
15.2.3. Dopamine Agonists
15.2.4. Immunomodulatory Drugs
15.2.5. Others
15.3. Market Attractiveness, by Drug Type
15.4. Market Value Forecast, by Indication Type, 2020-2034
15.4.1. Parkinson's Disease
15.4.2. Alzheimer's Disease
15.4.3. Multiple Sclerosis
15.4.4. Huntington Disease
15.4.5. Others
15.5. Market Attractiveness, by Indication Type
15.6. Market Value Forecast, by Route of Administration, 2020-2034
15.6.1. Oral
15.6.2. Parenteral
15.6.3. Transdermal
15.7. Market Attractiveness, by Route of Administration
15.8. Market Value Forecast, by End-user, 2020-2034
15.8.1. Hospital Pharmacies
15.8.2. Retail Pharmacies
15.8.3. Online Pharmacies
15.9. Market Attractiveness, by End-user
15.10. Market Value Forecast, by Country/Sub-region, 2020-2034
15.10.1. GCC Countries
15.10.2. South Africa
15.10.3. Rest of Middle East & Africa
15.11. Market Attractiveness Analysis
15.11.1. By Drug Type
15.11.2. By Indication Type
15.11.3. By Route of Administration
15.11.4. By End-user
15.11.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
16.2. Market Share Analysis, by Company (2023)
16.3. Company Profiles
16.3.1. Biogen
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Merck & Co., Inc.
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. Novartis AG
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. Teva Pharmaceutical Industries Ltd.
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Orion Corporation
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. UCB
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. Acadia Pharmaceuticals Inc.
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Mitsubishi Chemical Group Corporation
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. H. Lundbeck A/S
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
16.3.10. Denali Therapeutics
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Product Portfolio
16.3.10.3. Financial Overview
16.3.10.4. SWOT Analysis
16.3.10.5. Strategic Overview
16.3.11. Aquinnah Pharmaceuticals
16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.11.2. Product Portfolio
16.3.11.3. Financial Overview
16.3.11.4. SWOT Analysis
16.3.11.5. Strategic Overview
16.3.12. Prevail Therapeutics
16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.12.2. Product Portfolio
16.3.12.3. Financial Overview
16.3.12.4. SWOT Analysis
16.3.12.5. Strategic Overview
16.3.13. AZTherapies, Inc.
16.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
